Correlation between PET/CT parameters and KRAS expression in colorectal cancer

Clinical Nuclear Medicine

Volumn 39, Issue 8, 2014, Pages 685-689

  Chen, Shang Wen ^a,b,c   Chiang, Hua Che ^d   Chen, William Tzu Liang ^b,d   Hsieh, Te Chun ^e,f   Yen, Kuo Yang ^e,f   Chiang, Shu Fen ^e   Kao, Chia Hung ^b,e  

^a China Medical University Hospital   (China)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Departments of Surgery   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (China)

Author keywords

colorectal cancer (CRC); KRAS mutation; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RADIOPHARMACEUTICAL AGENT; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GLYCOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECTUM CANCER; TUMOR VOLUME; WILD TYPE; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; STATISTICAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS; RADIOPHARMACEUTICALS; RAS PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84904046568     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000481     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. Ca Cancer J Clin. 2011;61:69-90.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048. (Pubitemid 350106711)
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancers. N Engl J Med. 2008;359: 1757-1765.
4. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379. (Pubitemid 351171687)
5. Amado IG, Wolf M, Peters M, et al. Wild-type KRAS is required for panitumumab efficiency in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
6. Kawada K, Nakamoto Y, Kawada M, et al. Relationship between 18Ffluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res. 2012;18:1696-1703.
7. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
8. Sanz-Pamplona R, Cordero D, Berenguer A, et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011;17:7303-7312.
9. Kao CH, Lin SC, Hsieh TC, et al. Use of pretreatment metabolic tumor volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1297-1305.
10. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298-303. (Pubitemid 17075080)
11. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
12. Chen SW, Chen WTL, Yen KY, et al. Which FDG/PET parameters of the primary tumors in colon or sigmoid cancer provide the best correlation with the pathological findings? Eur J Radiol. 2013;82:405-410.
13. van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360: 1408-1417.
14. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced nonYsmall-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962-972.
15. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiYepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27: 2091-2096.
16. Lambrecht M,Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol. 2010;96:339-346.
17. Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007;6:31-36. (Pubitemid 46385905)
18. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96:302-307.
19. Grassetto G, Marzola MC, Minicozzi A, et al. F-18 FDG PET/CT in rectal carcinoma: where are we now? Clin Nucl Med. 2011;36:884-884.
20. Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317-322. (Pubitemid 28219093)
21. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24S-42S. (Pubitemid 351948035)
22. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820-1827.
23. Li FY, Lai MD. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B. 2009;10:219-229.
24. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
25. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945. (Pubitemid 46909922)
26. Maffione AM, Chondrogiannis S, Marzola MC, et al. Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer. Clin Nucl Med. 2014;39:215-219.
27. Wang X, Liu X, Li AYJ, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011;17: 2570-2580.
28. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853-864.
29. Maffione AM, Ferretti A, Chondrogiannis S, et al. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria. Clin Nucl Med. 2013;38:795-797.